Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial.
Saved in:
| Title: | Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial. |
|---|---|
| Authors: | Porter JC; UCL Respiratory, University College London, London, United Kingdom.; University College London Hospitals NHS Trust, London, United Kingdom., Inshaw J; Exploristics, Belfast, Ireland., Solis VJ; University College London Hospitals NHS Trust, London, United Kingdom., Denneny E; UCL Respiratory, University College London, London, United Kingdom.; University College London Hospitals NHS Trust, London, United Kingdom., Evans R; University College London Hospitals NHS Trust, London, United Kingdom., Temkin MI; Antimicrobial Defence Lab, The Francis Crick Institute, London, United Kingdom., De Vasconcelos N; Antimicrobial Defence Lab, The Francis Crick Institute, London, United Kingdom., Aramburu IV; Antimicrobial Defence Lab, The Francis Crick Institute, London, United Kingdom., Hoving D; Antimicrobial Defence Lab, The Francis Crick Institute, London, United Kingdom., Basire D; UCL Respiratory, University College London, London, United Kingdom., Crissell T; University College London Hospitals NHS Trust, London, United Kingdom., Guinto J; University College London Hospitals NHS Trust, London, United Kingdom., Webb A; University College London Hospitals NHS Trust, London, United Kingdom., Esmail H; University College London Hospitals NHS Trust, London, United Kingdom.; National Institute for Health Research, University College London Hospital Biomedical Research Centre, London, United Kingdom., Johnston V; University College London Hospitals NHS Trust, London, United Kingdom.; National Institute for Health Research, University College London Hospital Biomedical Research Centre, London, United Kingdom., Last A; University College London Hospitals NHS Trust, London, United Kingdom.; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom., Rampling T; University College London Hospitals NHS Trust, London, United Kingdom.; National Institute for Health Research, University College London Hospital Biomedical Research Centre, London, United Kingdom., Lippert L; Charité - Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany., Helbig ET; Charité - Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany., Kurth F; Charité - Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany., Williams B; University College London Hospitals NHS Trust, London, United Kingdom.; National Institute for Health Research, University College London Hospital Biomedical Research Centre, London, United Kingdom., Flynn A; Exploristics, Belfast, Ireland., Lukey PT; Target to Treatment Consulting Ltd, Stevenage, United Kingdom., Birault V; Translation, The Francis Crick Institute, London, United Kingdom., Papayannopoulos V; Antimicrobial Defence Lab, The Francis Crick Institute, London, United Kingdom. |
| Source: | ELife [Elife] 2024 Jul 16; Vol. 12. Date of Electronic Publication: 2024 Jul 16. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
